Antivirale Eigenschaften des Extrakts aus Cistus × incanus L. Pandalis auch bei SARS-CoV-2 in vitro nachgewiesen

Translated title of the contribution: Antiviral properties of Cistus × incanus LPandalis proven in SARS-CoV-2 in vitro

Jens Martin Träder*

*Corresponding author for this work


Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2, researchers are looking for promising and effective therapy in substances that are already available. The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis ®(CPE) has in vitro antiviral properties against SARS-CoV-2. CPE has already proved to be effective against several other viruses. At the Fraunhofer Institute for Cell Therapy and Immunology (IZI), cell cultures treated with Cystus Pandalis ®extract were infected with SARS-CoV-2, and the reduction in the infection rate was evaluated by comparing focus-forming units. An almost complete reduction in the CPE infection rate was observed at concentrations of greater than 15.6 μg/ml with a calculated EC 50(mean effective concentration) of 1.94 μg/ml. The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes, whereby CPE acts as an entry inhibitor. The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2.

Translated title of the contributionAntiviral properties of Cistus × incanus LPandalis proven in SARS-CoV-2 in vitro
Original languageGerman
JournalZeitschrift fur Phytotherapie
Issue number3
Pages (from-to)121-126
Number of pages6
Publication statusPublished - 01.06.2021

Research Areas and Centers

  • Research Area: Center for Population Medicine and Public Health (ZBV)

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19


Dive into the research topics of 'Antiviral properties of Cistus × incanus LPandalis proven in SARS-CoV-2 in vitro'. Together they form a unique fingerprint.

Cite this